The Canadian government is proposing changes to make it easier to conduct non-therapeutic cannabis research in the country and to foster more investigation into the development of cannabis products.

In a notice outlining the proposed changes, the department of health (Health Canada) said the current system sets a bar that is hard for some to reach. “Many researchers face difficulties in meeting the requirements of the clinical trial framework under the Food and Drug Regulations,” the department wrote. “These challenges have led to missed opportunities to advance knowledge about the use and effects of legal, regulated cannabis products available to adult consumers under the Cannabis Act. In turn, this knowledge gap limits Canadians’ ability to make informed decisions about their consumption of cannabis products and its associated risks.”

Read full article
I'm already a subscriber
Author default picture

CannIntelligence

This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization